St. Jude Medical, Inc.
STJ
New York Stock Exchange80.82
USD
+0.01
- -
St. Jude Medical, Inc.
STJ
(New York Stock Exchange)
Recent
price
80.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- St. Jude Medical, Inc. (STJ) develops, manufactures and distributes cardiovascular medical devices worldwide; its core products include mechanical and tissue heart valves, implantable cardioverter-defibrillators, pacemakers with quadripolar lead technology, cardiac resynchronization therapy devices, electrophysiology catheters, vascular closure systems such as Angio-Seal, cardiac mapping and visualization systems, optical coherence tomography imaging platforms like Ilumen Optis, structural heart repair products, neurostimulation devices for chronic pain management and heart failure monitoring solutions including CardioMEMS; the company targets physicians and healthcare providers serving patients with cardiac rhythm disorders, structural heart disease, atrial fibrillation and vascular conditions, with major operations spanning the United States, Europe, Latin America, Asia-Pacific and more than 100 countries overall from over 20 manufacturing facilities. Founded in 1976 and headquartered in Little Canada, Minnesota, the company maintains technology centers in locations including Brussels, Beijing, Tokyo, Austin and St. Paul to support physician training and procedure simulation. St. Jude Medical underwent a major strategic shift with its $25 billion acquisition by Abbott Laboratories, completed in January 2017, integrating its portfolio into Abbott's medical device business while divesting certain vascular closure assets to Terumo Corporation for $1.12 billion in late 2016; subsequent operational changes encompassed leadership transition to Michael T. Rousseau as CEO in 2016 and business reorganization into consolidated research/development and manufacturing/supply chain divisions.
My Pension Expert mooted sale and the read-across implications for St James's Place
Deutsche Bank backs St James's Place to top £30 by 2030 despite share weakness
St James Place has 40% more upside suggests US bank